Surpassing $1 billion in annual sales marks a major milestone for any biopharmaceutical company, and Acadia Pharmaceuticals (ACAD) is steadily moving toward that goal. Driven by continued commercial growth across its key products and expanding market opportunities, the company is positioning itself for its next phase of long-term success.
Acadia is focused on developing drugs for underserved neurological and rare disease communities around the world. Its commercial portfolio includes Nuplazid, the first and only FDA-approved therapy for Parkinson's disease psychosis, and Daybue, the first approved treatment for Rett syndrome.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.